<DOC>
	<DOC>NCT02553928</DOC>
	<brief_summary>Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.</brief_summary>
	<brief_title>Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinical visits during the study. The patient has a diagnosis of probable AD consistent with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDSADRDA) criteria. The patient has a Mini Mental State Examination (MMSE) score ≥ 5 and ≤ 18 at Screening visit The dose of Memantine has been stable at 20 mg once a day for at least 3 month prior to screening. The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the IMP or its excipients. The patient has one or more of the following conditions: Evidence and/or history of any clinically significant neurodegenerative disease or other serious neurological disorders other than Alzheimer's disease including, but not limited to, Lewy body dementia, FrontoTemporal dementia, Parkinson's disease, Huntington's disease, major cortical stroke, Multiple Sclerosis, major head trauma and primary or secondary cerebral neoplasm. The patient has a modified Hachinski ischemia score greater than 4 at the screening visit. The patient has any current psychiatric disorder or Axis I disorder (DSMIVTR™ criteria), established as the primary diagnosis, other than AD The patient is currently receiving treatment with an unstable dose of acetyl cholinesterase inhibitor The patients has clinical significant abnormal screening values ( vital signs, laboratory, ecg, B12. Other protocol defined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>